Eliglustat
CAS: 491833-29-5
Ref. 3D-FD158477
| 10mg | 180.00 € | ||
| 25mg | 271.00 € | ||
| 50mg | 406.00 € | ||
| 100mg | 580.00 € | ||
| 250mg | 951.00 € |
Product Information
- N-[(1R,2R)-2-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2-hydroxy-1-(1-pyrrolidinylmethyl)ethyl]octanamide
Eliglustat is an investigational drug for the treatment of hepatic steatosis. Eliglustat is a complex enzyme inhibitor that blocks the synthesis of glucosylceramide and prevents the accumulation of lipids in the liver. It has been shown in animal studies to have long-term efficacy in preventing hepatic steatosis and improving disease activity. The median plasma concentration of eliglustat is approximately 1,000 times higher than other drugs that inhibit glucosylceramide synthesis. Although eliglustat has not been approved by the FDA, it has been shown to be safe and effective in clinical trials involving patients with chronic viral hepatitis B or C infection.
Chemical properties
Technical inquiry about: 3D-FD158477 Eliglustat
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
